Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.
Earnings for Longeveron Inc. (LGVN)
Earnings in 2023 (TTM): $-21,413,000
According to Longeveron Inc.'s latest financial reports the company's current earnings (TTM) are $-21,413,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Longeveron Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-21,413,000 | $-21,413,000 |
| 2022 | $-18,835,000 | $-19,627,000 |
| 2021 | $-17,045,000 | $-17,164,000 |
| 2020 | $-3,720,808 | $-3,791,220 |
| 2019 | $-2,959,877 | $-2,995,507 |
| 2018 | $-6,336,796 | $-6,336,796 |